Wave Life Sciences Ltd. (WVE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-02. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 33/100 (MEDIUM), 66.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.57% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
- Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
- Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
- Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
- Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
- Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
- Wave Life Sciences to Present at Upcoming Investor Conferences
- Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Wave Life Sciences Ltd..
Full WVE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.